Literature DB >> 21556932

Expression of GPC3 protein and its significance in lung squamous cell carcinoma.

Qiang Lin1, Li-Wen Xiong, Xu-Feng Pan, Jun-Feng Gen, Guo-Liang Bao, Hui-Fang Sha, Jiu-Xian Feng, Chun-Yu Ji, Ming Chen.   

Abstract

The purpose of this study was to investigate GPC3 gene expression in lung squamous cell carcinoma tissue and its correlation with clinical and tumor characteristics. Using RT-PCR, the presence of GPC3 gene expression was detected in cancer tissue and adjacent normal tissue in 66 cases of lung squamous cell carcinoma and positive rates were calculated. Using Western blot, changes in GPC3 protein expression were detected in lung squamous cell carcinoma and adjacent normal tissues. The percentage of tissue samples expressing GPC3 mRNA was significantly higher in lung squamous cell carcinoma than in adjacent normal tissue (P < 0.05). This percentage was also significantly higher for cases with lymph node metastasis than for those without lymph node metastasis (P < 0.05). Further, the percentage of samples expressing GPC3 mRNA was higher with lowering degrees of tumor differentiation (P < 0.05). Rates of GPC3 expression were, however, independent of patient gender, age, and tumor size (P > 0.05). The expression of GPC3 protein in lung squamous cell carcinoma was significantly higher than that in adjacent normal tissues (P < 0.05). The expression in cases with lymph node metastasis was significantly higher than in those without lymph node metastasis (P < 0.05), and GPC3 protein expression increased with lowering degrees of tumor differentiation (P < 0.05). Further investigation is warranted for the association of initiation, development, invasion, and metastasis of disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21556932     DOI: 10.1007/s12032-011-9973-1

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  26 in total

1.  Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma.

Authors:  S S Murthy; T Shen; A De Rienzo; W C Lee; P C Ferriola; S C Jhanwar; B T Mossman; J Filmus; J R Testa
Journal:  Oncogene       Date:  2000-01-20       Impact factor: 9.867

2.  Up-regulation of glypican-3 in human hepatocellular carcinoma.

Authors:  Masahiro Suzuki; Kazushi Sugimoto; Junichiro Tanaka; Masahiko Tameda; Yuji Inagaki; Satoko Kusagawa; Keiichiro Nojiri; Tetsuya Beppu; Kentaro Yoneda; Norihiko Yamamoto; Masaaki Ito; Misao Yoneda; Kazuhiko Uchida; Koujiro Takase; Katsuya Shiraki
Journal:  Anticancer Res       Date:  2010-12       Impact factor: 2.480

3.  The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma.

Authors:  Naoko Yamauchi; Akira Watanabe; Michiyo Hishinuma; Ken-Ichi Ohashi; Yutaka Midorikawa; Yasuyuki Morishita; Toshiro Niki; Junji Shibahara; Masaya Mori; Masatoshi Makuuchi; Yoshitaka Hippo; Tatsuhiko Kodama; Hiroko Iwanari; Hiroyuki Aburatani; Masashi Fukayama
Journal:  Mod Pathol       Date:  2005-12       Impact factor: 7.842

4.  Glypican-3 expression in Wilms tumor and hepatoblastoma.

Authors:  J A Toretsky; N L Zitomersky; A E Eskenazi; R W Voigt; E D Strauch; C C Sun; R Huber; S J Meltzer; D Schlessinger
Journal:  J Pediatr Hematol Oncol       Date:  2001-11       Impact factor: 1.289

5.  Glypican-3 expression is silenced in human breast cancer.

Authors:  Y Y Xiang; V Ladeda; J Filmus
Journal:  Oncogene       Date:  2001-11-01       Impact factor: 9.867

6.  Disruption of the non-canonical WNT pathway in lung squamous cell carcinoma.

Authors:  Eric H L Lee; Raj Chari; Andy Lam; Raymond T Ng; John Yee; John English; Kenneth G Evans; Calum Macaulay; Stephen Lam; Wan L Lam
Journal:  Clin Med Oncol       Date:  2008-04-01

7.  Identification of glypican-3 as a novel tumor marker for melanoma.

Authors:  Tetsuya Nakatsura; Toshiro Kageshita; Shosuke Ito; Kazumasa Wakamatsu; Mikio Monji; Yoshiaki Ikuta; Satoru Senju; Tomomichi Ono; Yasuharu Nishimura
Journal:  Clin Cancer Res       Date:  2004-10-01       Impact factor: 12.531

8.  Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome.

Authors:  G Pilia; R M Hughes-Benzie; A MacKenzie; P Baybayan; E Y Chen; R Huber; G Neri; A Cao; A Forabosco; D Schlessinger
Journal:  Nat Genet       Date:  1996-03       Impact factor: 38.330

9.  The heparan sulfate proteoglycan GPC3 is a potential lung tumor suppressor.

Authors:  Han Kim; Guo-Liang Xu; Alain C Borczuk; Steve Busch; Jorge Filmus; Mariana Capurro; Jerome S Brody; Jennifer Lange; Jeanine M D'Armiento; Paul B Rothman; Charles A Powell
Journal:  Am J Respir Cell Mol Biol       Date:  2003-06-19       Impact factor: 6.914

10.  Inhibition of invasion and metastasis by glypican-3 in a syngeneic breast cancer model.

Authors:  M G Peters; E Farías; L Colombo; J Filmus; L Puricelli; E Bal de Kier Joffé
Journal:  Breast Cancer Res Treat       Date:  2003-07       Impact factor: 4.872

View more
  14 in total

Review 1.  Heparan sulfate signaling in cancer.

Authors:  Erik H Knelson; Jasmine C Nee; Gerard C Blobe
Journal:  Trends Biochem Sci       Date:  2014-04-19       Impact factor: 13.807

2.  Role of Glypican-3 in the growth, migration and invasion of primary hepatocytes isolated from patients with hepatocellular carcinoma.

Authors:  Mauro Montalbano; Cristiana Rastellini; Joshua T McGuire; Janika Prajapati; Ali Shirafkan; Renza Vento; Luca Cicalese
Journal:  Cell Oncol (Dordr)       Date:  2017-12-04       Impact factor: 6.730

Review 3.  Molecular principles of metastasis: a hallmark of cancer revisited.

Authors:  Jawad Fares; Mohamad Y Fares; Hussein H Khachfe; Hamza A Salhab; Youssef Fares
Journal:  Signal Transduct Target Ther       Date:  2020-03-12

4.  Prognostic and clinicopathological significance of glypican-3 overexpression in hepatocellular carcinoma: a meta-analysis.

Authors:  Jia Li; Jian-Zhi Gao; Jing-Li Du; Li-Xin Wei
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

Review 5.  Heparan Sulfate and Heparan Sulfate Proteoglycans in Cancer Initiation and Progression.

Authors:  Arvindhan Nagarajan; Parmanand Malvi; Narendra Wajapeyee
Journal:  Front Endocrinol (Lausanne)       Date:  2018-08-24       Impact factor: 5.555

Review 6.  Glypican 3-Targeted Therapy in Hepatocellular Carcinoma.

Authors:  Takahiro Nishida; Hiroaki Kataoka
Journal:  Cancers (Basel)       Date:  2019-09-10       Impact factor: 6.639

Review 7.  Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma.

Authors:  Meng Guo; Hailing Zhang; Jianming Zheng; Yangfang Liu
Journal:  J Cancer       Date:  2020-02-03       Impact factor: 4.207

8.  A novel panel of biomarkers in distinction of small well-differentiated HCC from dysplastic nodules and outcome values.

Authors:  Guang-Zhi Jin; Hui Dong; Wen-Long Yu; Yan Li; Xin-Yuan Lu; Hua Yu; Zhi-Hong Xian; Wei Dong; Yin-Kun Liu; Wen-Ming Cong; Meng-Chao Wu
Journal:  BMC Cancer       Date:  2013-03-27       Impact factor: 4.430

9.  GPC3 expression in mouse ovarian cancer induces GPC3‑specific T cell-mediated immune response through M1 macrophages and suppresses tumor growth.

Authors:  Chenhong Luo; Kiyosumi Shibata; Shiro Suzuki; Hiroaki Kajiyama; Takeshi Senga; Yoshihiro Koya; Mina Daimon; Mamoru Yamashita; Fumitaka Kikkawa
Journal:  Oncol Rep       Date:  2014-07-02       Impact factor: 3.906

10.  Elevated GPC3 level promotes cell proliferation in liver cancer.

Authors:  Shanshan Wang; Ning Chen; Yuhan Chen; Lin Sun; Li Li; Hui Liu
Journal:  Oncol Lett       Date:  2018-05-21       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.